Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bay National Corp. (OTC: BAYN).

Full DD Report for BAYN

You must become a subscriber to view this report.

Recent News from (OTC: BAYN)

Key Upcoming Oncology Clinical Trial Catalysts
With cancer immunotherapies driving an explosion in oncology clinical trials, it’s becoming increasingly difficult to keep track of key clinical trial activity and potential catalysts. We've analyzed all oncology trials in and have identified the near term "high imp...
Source: SeekingAlpha
Date: March, 05 2018 17:43
Biotech Analysis Central Pharma News: Regeneron's Flop, Viking's Trial Success, Biogen's MS Deal
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Regeneron's Phase 2 Combo Trial Fails to Achieve Success In Eye Diseases News: On Monday November 27, 2017 Regeneron Pharmaceuticals ( REGN ) announc...
Source: SeekingAlpha
Date: November, 29 2017 02:01
Biotech Analysis Central: Daily Pharma News - October 17, 2017
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Exelixis Announces Positive Phase 3 Liver Cancer Data, and Priority Review For Kidney Cancer drug News: On Monday, Exelixis ( EXEL ) with its partner...
Source: SeekingAlpha
Date: October, 17 2017 04:36
Nektar Makes A Stride Forward In Resolving Autoimmune Diseases
On Monday, Nektar Therapeutics ( NKTR ) announced that it had reached a deal with Eli Lilly ( LLY ) to develop NKTR-358. This drug compound is an immunological drug compound that the company has developed and brought up to phase 1 studies. The drug in question is being partnered to primarily...
Source: SeekingAlpha
Date: July, 25 2017 16:10
No Fruitful Harvest For Farmland Partners
Yesterday, I wrote an article on small-cap REITs and I explained that "as investors become more familiar with a new property type and develop a better sense of risk, they may find reason to reduce their assessment of risk, and that may prompt an upward revaluation of the property." That ha...
Source: SeekingAlpha
Date: July, 21 2017 11:54
My 75 Stock January 2017 Portfolio Update: Buying 1 New Stock (Toronto-Dominion Bank) And More Cisco
January saw the inauguration of President Trump and markets reacting promptly to any tweets Mr. Trump sends. Stocks are repeatedly hitting all-time highs, and with overall S&P 500 valuation already above 25-times earnings, it gets more and more difficult to find attractively priced stocks ...
Source: SeekingAlpha
Date: February, 14 2017 09:15
SenesTech Reduces IPO Price To Stoke Investor Interest
Rodent pest control technology company SenesTech (SNES)has reduced the expected price range for its IPO. SNES previously offered to sell 2 million shares at a midpoint price of $13 per share. It has now lowered the midpoint price to $10 per share, representing a 23% price reduction. I ha...
Source: SeekingAlpha
Date: November, 14 2016 10:52
My 71 Stock October 2016 Portfolio Update: 71 Stocks, Buying Altria, AbbVie And AT&T For Value
It's earnings season in October and despite results being pretty solid, Mr. Market didn't really appreciate them and instead sent many, many stocks down, among others e.g. Amazon (AMZN), Apple (AAPL), Gilead (GILD), AbbVie (ABBV), B&G Foods (BGS). Thus, my portfolio performance in October ...
Source: SeekingAlpha
Date: November, 07 2016 15:22
SenesTech IPO - Humane Pest Control For The Future
Quick Take SenesTech (SNES) wants to raise up to $31.75 million in an IPO for its ContraPest rodent population control technologies. We don't know IPO valuation or revenue forecasts, but based on typical chemical industry royalty rates, the company's manufacturing & distribution pa...
Source: SeekingAlpha
Date: September, 24 2016 22:35


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BAYN.

About Bay National Corp. (OTC: BAYN)

Logo for Bay National Corp. (OTC: BAYN)

Bay Bank was formed to serve the needs of the local community with exceptional personal attention and thoughtful financial solutions. We are a team of experienced bankers with the ability to listen, the agility to make decisions, and the resolve to follow through on behalf of our customers.


Contact Information



Current Management

  • Hugh A. Mohler / President, CEO
  • Mark A. Semanie / CFO

Current Share Structure

  • Market Cap: $21,513 - 03/09/2018
  • Issue and Outstanding: 2,151,301 - 08/14/2008


Daily Technical Chart for (OTC: BAYN)

Daily Technical Chart for (OTC: BAYN)

Stay tuned for daily updates and more on (OTC: BAYN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BAYN)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BAYN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BAYN and does not buy, sell, or trade any shares of BAYN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: